DOV focus shifts away from bicifadine

Executive Summary

DOV Pharmaceutical is implementing a new strategic direction "in which the company will focus its internal efforts on its Phase I and II clinical and preclinical research programs for the development and discovery of drugs to treat neuropsychiatric disorders," the firm announces Oct. 10. Those programs include the firm's triple reuptake inhibitors and preclinical GABA modulators. While DOV had previously been focused on the late stage trials of the analgesic bicifadine, it appears the company now looks at bicifadine as a prime partnering opportunity. DOV is stopping patient dosing in a Phase III back pain trial "in order to best allocate resources"...